10/9/2006 | BT | Market Commentary: New River rises 61.5%, Shire up 16% on ADHD drug nod; Coley eyed; NeoPharm higher by 20%
|
10/9/2006 | BT | Market Commentary: New River rises 61.5%, Shire up 16% on ADHD drug nod; Coley eyed; NeoPharm higher by 20%
|
9/21/2006 | BT | JMP reiterates NeoPharm at strong buy
|
9/18/2006 | BT | Neopharm: Median survival time hits 44 weeks in cintredekin besudotox trial
|
8/10/2006 | BT | JMP reiterates NeoPharm at strong buy
|
7/19/2006 | BT | Market Commentary: Amgen up slightly ahead of earnings; Isis, NeoPharm, Genta up; Affymetrix off, Illumina up 29%
|
6/23/2006 | BT | NeoPharm reiterated at strong buy
|
6/22/2006 | BT | NeoPharm to continue Precise trial to final efficacy analysis at 215 deaths
|
6/22/2006 | BT | Merrill maintains NeoPharm at neutral
|
6/22/2006 | BT | Market Commentary: Gene Logic plunges 36%; ISTA off; MedImmune convertible on deck; American Medical issues higher
|
6/16/2006 | BT | NeoPharm maintained at buy by Merrill
|
6/9/2006 | BT | NeoPharm reiterated at strong buy by JMP
|
6/8/2006 | BT | NeoPharm: phase 3 trial in brain cancer treatment reaches criteria for interim analysis
|
5/30/2006 | BT | NeoPharm begins enrollment of up to 54 patients in phase 2 trial of LE-SN38 for colorectal cancer
|
5/30/2006 | BT | JMP's Biotechnology Industry Overview
|
5/8/2006 | BT | Merrill keeps NeoPharm at buy
|
5/5/2006 | BT | JMP reiterates NeoPharm at strong buy
|
5/5/2006 | BT | Market Commentary: Northstar Neuroscience stock climbs on upsized IPO; Praecis stock jumps 22.3% on earnings
|
5/5/2006 | BT | NeoPharm says first-quarter net loss decreases to $8.1 million
|
5/4/2006 | BT | NeoPharm reiterated at strong buy by JMP
|
5/1/2006 | BT | NeoPharm maintains Merrill's buy rating
|
5/1/2006 | BT | Market Commentary: Teva shares, convertibles gain on Zocor ruling; NeoPharm off amid downsizing; Alnylam, Idenix drop
|
4/28/2006 | BT | NeoPharm program to reduce expenses by $7 million
|
4/26/2006 | BT | Neopharm says software-based catheter enhances treatment for brain tumor patients
|
4/26/2006 | BT | NeoPharm at strong buy rating from JMP
|
4/25/2006 | BT | NeoPharm phase 1 study suggests cintredekin besudotox effective in brain tumor patients
|
4/25/2006 | BT | NeoPharm reiterated at buy by JMP
|
4/24/2006 | BT | NeoPharm's recombinant protein increases life expectancy in patients with common malignant brain tumors
|
3/1/2006 | BT | NeoPharm maintained at buy by Merrill
|
3/1/2006 | BT | JMP puts NeoPharm at strong buy
|
2/9/2006 | BT | NeoPharm must submit more data to FDA before beginning cancer drug trial
|
1/18/2006 | BT | JMP says select small-, mid-cap biotech stocks look promising
|
1/10/2006 | BT | NeoPharm greenshoe exercised, raising deal to $38.5 million
|
1/5/2006 | BT | Market Commentary: Advancis sale of Keflex stumbles; Nuvelo spikes on Bayer pact; buyers snap up Nektar, MannKind
|
1/5/2006 | BT | New Issue: NeoPharm raises $35.7 million in spot sale at $10.20, versus $10.89 close
|
12/30/2005 | BT | JMP says NeoPharm still strong buy
|
12/30/2005 | BT | Committee recommends NeoPharm's phase 3 cintredekin besudotox trial continue as planned
|
12/30/2005 | BT | NeoPharm maintained by Merrill at buy
|
12/9/2005 | BT | NeoPharm's phase 3 trial of cintredekin besudotox for brain cancer achieves patient enrollment
|
12/5/2005 | BT | NeoPharm reiterated by JMP as strong buy
|
12/5/2005 | BT | Market Commentary: Noven soars on ADHD patch news; Ligand bounces on board expansion; Progenics off sharply
|
11/21/2005 | BT | NeoPharm reiterated at strong buy by JMP
|
11/21/2005 | BT | NeoPharm cintredekin besudotox trial reaches second futility analysis, will likely continue
|
11/21/2005 | BT | Merrill Lynch maintains NeoPharm at buy
|
11/11/2005 | BT | JMP maintains NeoPharm at strong buy
|
11/2/2005 | BT | Merrill maintains NeoPharm buy rating
|
11/2/2005 | BT | JMP reiterates NeoPharm at strong buy
|
10/31/2005 | BT | Merrill Lynch maintains NeoPharm at buy
|
10/31/2005 | BT | Market Commentary: NeoPharma skyrockets on new CEO; Charles River Labs higher; Nabi, Indevus, Invitrogen up
|
10/24/2005 | BT | Merrill Lynch reiterates buy for NeoPharm
|
10/19/2005 | BT | JMP reiterates NeoPharm at strong buy
|
10/19/2005 | BT | Market Commentary: Predix IPO on deck; Indevus up; Generex up; NeoPharm gains; Amgen plunges; Genta climbs
|
10/11/2005 | BT | JMP reiterates NeoPharm as strong buy
|
10/4/2005 | BT | NeoPharm kept at strong buy by JMP
|
9/22/2005 | BT | NeoPharm maintained by JMP at strong buy
|
8/25/2005 | BT | NeoPharm reiterated by JMP at buy
|
8/24/2005 | BT | NeoPharm reiterated by Merrill at buy
|
8/8/2005 | BT | NeoPharm price target raised by Merrill
|
8/1/2005 | BT | NeoPharm kept by JMP at strong buy
|
7/14/2005 | BT | NeoPharm initiated by Merrill at buy
|